Table 2 Analysis of serum and urine biomarkers before and after changing to tenofovir alafenamide among 31 patients

Serum creatinine (mg/dL)

0.89 (0.68–1.16)

0.90 (0.66–1.11)

0.89 (0.6–1.25)

Estimated GFR using creatinine

73.1 (50.1–108.4)

72.6 (53.2–110.2)

74.8 (47.2–123.3)

Serum cystatin C (mg/L)

0.88 (0.65–1.39)

0.87 (0.64–1.26)

0.88 (0.62–1.26)

Estimated GFR using cystatin C

91.2 (50.2–130.5)

91.5 (56.4–131.6)

92.3 (56.4–136.2)

Urine-NAG/urine-creatinine (U/g Cr)

3.72 (0–56.9)

5.31 (0.83–28.6)

3.93 (0–29.4)

Urine-L-FABP/urine-creatinine (μg/g Cr)

2.3 (0.6–63.9)

1.8 (0.6–31.2)

1.5 (0.3–15)

%TRP

85.1 (73.7–92.7)

87.7 (73.6–97.7)

86.9 (74.2–94.2)

Serum inorganic phosphorus (mg/dL)

3.1 (2.5–4.1)

3.0 (2.1–4.3)

3.1 (2.2–4.7)

Proteinuria (%)

13.3

6.67

6.67

Urine occult blood: positive (%)

6.7

6.7

10

Serum LDL-cholesterol (mg/dL)

106 (67–159)

132 (84–199)

119 (82–207)

Serum triglyceride (mg/dL)

144 (41–874)

146 (47–700)

175 (43–669)

Serum BAP (μg/L)

10.8 (7.0–21.6)

11.7 (6.2–21.1)

11.0 (7.4–19.8)

Urine NTx/urine Cr (nmol/mmol Cr)

48 (27.4–84.9)

37 (20.2–83.4)

32.8 (14.7–67.4)